BRD2 and breast cancer: The EU summary of product characteristics for triptorelin and leuprorelin in adjuvant BC advises initiating the GnRHa 6-8 weeks before the AI, checking E2/FSH before starting the AI, and performing serial hormone-level testing during AI therapy to avoid AI-induced rebound increase in circulating estrogen, with consequential implications for BC.37,38 Our results suggest that education is required to standardize initiation of GnRHa therapy.